 multimod cisplatin treatment nonresect alpha-fetoprotein-posit hepatoma twenty-eight patient alpha-fetoprotein-posit afp+ nonresect hepatoma new multimod phase II program induct therapi intraven cisplatin cgi irradi tumor volum fraction day hepat arteri infus cisplatin ia-cddp monthli interv patient induct cycl ia-cddp twelve-month cumul surviv patient patient induct ia-cddp median surviv respons rate complet partial overal patient treatment improv surviv present seri patient minim hematolog toxic possibl integr new modal therapi